{"gene":"SSX2","run_date":"2026-06-10T07:46:41","timeline":{"discoveries":[{"year":1995,"finding":"SSX2 protein contains an N-terminal domain with homology to the Kruppel-associated box (KRAB), a transcriptional repressor domain previously found only in Kruppel-type zinc finger proteins, establishing SSX2 as a putative transcriptional repressor.","method":"Sequence analysis and structural homology identification","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — sequence-based domain identification replicated across multiple independent studies confirming KRAB-like domain","pmids":["7539744"],"is_preprint":false},{"year":2002,"finding":"SSX2 physically interacts with two novel proteins, RAB3IP (human homologue of a Ras-like GTPase Rab3A interactor) and SSX2IP, via its N-terminal moiety; RAB3IP is normally cytoplasmic but co-expression with SSX2 results in its nuclear relocalization; both interactions were confirmed by yeast two-hybrid and GST pull-down assays in vitro.","method":"Yeast two-hybrid, GST pull-down, immunofluorescence of transfected cells","journal":"Genes, chromosomes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal methods (yeast two-hybrid + in vitro GST pull-down + co-localization), single lab","pmids":["12007189"],"is_preprint":false},{"year":2006,"finding":"The SYT-SSX2 fusion protein recruits beta-catenin to the nucleus and forms a transcriptionally active nuclear complex with beta-catenin; depletion of SYT-SSX2 in primary synovial sarcoma cells caused loss of nuclear beta-catenin signal and decreased beta-catenin signaling activity. This nuclear localization was independent of canonical Wnt signaling pathways.","method":"Co-immunoprecipitation, immunofluorescence, siRNA knockdown in primary synovial sarcoma cells, luciferase reporter assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, KD with defined phenotype, reporter assay; single lab but multiple orthogonal methods","pmids":["16462762"],"is_preprint":false},{"year":2006,"finding":"SYT-SSX2 interacts preferentially with the transcriptional repressor Slug (not Snail), preventing Slug from binding the proximal E-cadherin promoter, thereby derepressing E-cadherin transcription; this was shown by co-immunoprecipitation and chromatin immunoprecipitation, and confirmed by luciferase reporter assays showing SYT-SSX2 overcomes Slug-mediated E-cadherin repression.","method":"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP, and reporter assay in single lab with three orthogonal methods","pmids":["16849535"],"is_preprint":false},{"year":2006,"finding":"The SS18-SSX2 fusion protein acts as a transcriptional activator-repressor that induces epigenetic gene deregulation, including altered histone modifications at the CD44 and IGF2 promoters and changes in DNA methylation at the IGF2 imprinting control region; SS18 normally associates with SWI/SNF (coactivator) and SSX associates with polycomb (corepressor), and both activities are retained in the fusion protein.","method":"Conditional expression + cDNA microarray profiling, chromatin immunoprecipitation for histone modifications, bisulfite sequencing for DNA methylation","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal epigenetic assays, single lab","pmids":["17018603"],"is_preprint":false},{"year":2007,"finding":"SYT-SSX2 activates the ephrin (Eph/ephrin) signaling pathway, causing cytoskeletal remodeling including cell elongation and neurite-like extensions; blockade of EphB2 signaling reversed this aberrant cytoskeletal phenotype. Additionally, SYT-SSX2 independently stabilizes the microtubule network via accumulation of detyrosinated Glu-tubulin in a manner independent of ephrin signaling.","method":"Retroviral transduction, EphB2 blockade rescue experiment, immunofluorescence, immunohistochemistry of patient tissue","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional rescue by pathway blockade, two distinct mechanisms identified, single lab","pmids":["17686994"],"is_preprint":false},{"year":2009,"finding":"SYT-SSX2 interacts with the polycomb repressive complex and destabilizes the polycomb subunit Bmi1, resulting in impairment of polycomb-associated histone H2A ubiquitination and reactivation of polycomb target genes.","method":"Co-immunoprecipitation, western blot for Bmi1 stability, histone H2A ubiquitination assay, gene expression analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional histone modification assay plus target gene reactivation, single lab","pmids":["19337376"],"is_preprint":false},{"year":2011,"finding":"SYT-SSX2 reprograms mesenchymal stem cells (BMMSCs) and myogenic progenitors by directly occupying and upregulating neural-specific genes, committing cells to a pro-neural lineage while simultaneously impairing myogenic and adipogenic differentiation; FGFR2 was identified as a direct target gene occupied and upregulated by SYT-SSX2, and knockdown of FGFR2 abrogated growth and attenuated the neural phenotype in BMMSCs and synovial sarcoma cells.","method":"Retroviral transduction, ChIP, gene expression profiling, shRNA knockdown with phenotypic readout","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for direct occupancy, KD rescue, multiple cell types; single lab","pmids":["21996728"],"is_preprint":false},{"year":2012,"finding":"SS18-SSX2 directly suppresses expression of MCL1 and BCL2A1 anti-apoptotic genes by binding through ATF2 to cyclic AMP response elements (CRE) in their promoters and recruiting TLE1/Groucho, while concurrently increasing BCL2 expression; this pathway suppression renders synovial sarcoma cells sensitive to BH3-peptidomimetic ABT-263.","method":"ChIP, gene expression analysis, siRNA knockdown, in vitro cytotoxicity assay, in vivo mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct promoter binding with ATF2, functional pharmacological validation in vitro and in vivo; single lab","pmids":["22797074"],"is_preprint":false},{"year":2012,"finding":"SYT-SSX2 is recruited genome-wide predominantly to Polycomb-modified chromatin enriched with H3K27me3; H3K27me3 is the dominant epigenetic marker associated with SYT-SSX2 binding and gene expression regulation, and activated target genes tend to have SYT-SSX2/H3K27me3 sites within the gene body or near the TSS, while repressed genes show SYT-SSX2/H3K27me3 at long-range.","method":"Genome-wide ChIP-seq, epigenetic profiling, hierarchical clustering","journal":"BMC genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq with multiple histone marks; single lab","pmids":["22594313"],"is_preprint":false},{"year":2014,"finding":"SSX2 is a chromatin-associated protein that antagonizes BMI1 and EZH2 polycomb group (PcG) body formation, derepresses PcG target genes, and negatively regulates H3K27me3 levels in melanoma cells; SSX2 binds double-stranded DNA in a sequence non-specific manner; the antagonism of PcG function occurs through an indirect mechanism (likely modulation of chromatin structure) since SSX2 does not affect the overall composition and stability of PcG complexes.","method":"Immunofluorescence for PcG bodies, ChIP for H3K27me3, gene expression analysis, in vitro DNA-binding assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (ChIP, direct DNA-binding, PcG body imaging, gene expression), single lab","pmids":["25249625"],"is_preprint":false},{"year":2014,"finding":"Ectopic SSX2 expression in melanoma and breast cancer cells causes DNA damage, genomic instability (increased DNA content, enlarged nuclei, DNA double-strand breaks), p53-mediated G1 cell cycle arrest, and late apoptosis/senescence; knockdown of endogenous SSX2 in melanoma cell lines reduced cell growth, demonstrating that SSX2 supports tumor cell proliferation.","method":"Ectopic overexpression and siRNA knockdown, flow cytometry, γH2AX immunostaining for DNA damage, β-galactosidase senescence assay","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional (OE + KD) with multiple phenotypic readouts; single lab","pmids":["25363656"],"is_preprint":false},{"year":2016,"finding":"SSX2 knockdown in prostate cancer cells resulted in epithelial morphology, increased cell proliferation, increased expression of focal adhesion genes, decreased anchorage-independent growth, increased invasion, and increased in vivo tumorigenicity; overexpression had little effect on morphology. SSX2 does not drive epithelial-to-mesenchymal transition (EMT) in prostate cancer but is involved in focal adhesion loss associated with tumor cell dissemination.","method":"Knockdown and overexpression in prostate cancer cell lines, morphological analysis, gene expression profiling, invasion assay, in vivo tumorigenicity assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional genetic manipulation with multiple orthogonal phenotypic assays including in vivo; single lab","pmids":["27276714"],"is_preprint":false},{"year":2019,"finding":"The Mediator complex is essential for SSX2-induced senescence: knockdown of MED1, MED4, and MED14 prevented SSX2-induced senescence in cancer cells, whereas MED1 knockdown did not prevent B-Raf- or Epirubicin-induced senescence, indicating a specific link between Mediator and SSX2-mediated senescence.","method":"Functional genetic screen, siRNA knockdown of Mediator subunits, senescence assays (β-galactosidase, morphology), specificity controls","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional genetic screen plus orthogonal validation with specificity controls; single lab","pmids":["31695025"],"is_preprint":false},{"year":2021,"finding":"Ectopic SSX2 expression induces the formation of a novel type of intranuclear lamin bodies containing both A- and B-type lamins but no other nuclear lamina components; this lamin body formation is dependent on S-phase progression and is independent of SSX2 interactions with polycomb proteins or the Mediator complex.","method":"Immunofluorescence in breast epithelial cell lines, pharmacological S-phase block, component exclusion analysis","journal":"The international journal of biochemistry & cell biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, primarily immunofluorescence-based localization; mechanism of lamin body formation remains indirect","pmids":["34808373"],"is_preprint":false},{"year":2009,"finding":"The C-terminal nuclear localization signal (NLS) of SSX2 is required for its nuclear import; deletion of the NLS prevented nuclear localization and instead SSX2 accumulated in the endoplasmic reticulum in a misfolded state, while NLS-deleted SSX2 was correctly folded and secreted.","method":"Heterologous expression in Pichia pastoris, indirect immunofluorescence, deletion mutagenesis","journal":"Applied microbiology and biotechnology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional NLS identification by deletion, but performed in a yeast expression system for recombinant protein production purposes; single study","pmids":["19826807"],"is_preprint":false}],"current_model":"SSX2 is a nuclear, chromatin-associated transcriptional repressor that contains a KRAB-like domain, binds double-stranded DNA non-specifically, antagonizes polycomb group complex function (destabilizing Bmi1, reducing H3K27me3, derepressing PcG target genes), and — as the SYT-SSX2 oncogenic fusion — recruits beta-catenin to the nucleus, activates ephrin/EphB2-mediated cytoskeletal remodeling, suppresses MCL1/BCL2A1 via ATF2/TLE1 at CRE promoter elements, derepresses E-cadherin by sequestering Slug from its promoter, and reprograms mesenchymal stem cells toward a neural lineage by directly occupying H3K27me3-marked chromatin genome-wide; in its native (non-fusion) form, SSX2 supports tumor cell proliferation and induces genomic instability and senescence through a Mediator complex-dependent pathway."},"narrative":{"mechanistic_narrative":"SSX2 is a nuclear, chromatin-associated transcriptional repressor that antagonizes Polycomb group (PcG) function and modulates chromatin structure [PMID:7539744, PMID:25249625]. It carries an N-terminal KRAB-like repressor domain [PMID:7539744] and binds double-stranded DNA in a sequence non-specific manner, antagonizing BMI1/EZH2 PcG body formation, derepressing PcG target genes, and lowering H3K27me3 levels through an indirect mechanism that does not alter the composition or stability of PcG complexes [PMID:25249625]. In its native form, SSX2 supports tumor cell proliferation but, when ectopically expressed, induces DNA damage, genomic instability, and p53-dependent senescence, the latter requiring the Mediator complex (MED1/MED4/MED14) [PMID:25363656, PMID:31695025]. SSX2 also drives context-dependent changes in tumor cell adhesion and dissemination distinct from canonical EMT [PMID:27276714]. As the SYT(SS18)-SSX2 oncogenic fusion characteristic of synovial sarcoma, SSX2 contributes a Polycomb-corepressor activity combined with the SS18 SWI/SNF-coactivator activity to deregulate chromatin and gene expression genome-wide, binding preferentially to H3K27me3-marked chromatin [PMID:17018603, PMID:22594313]; through this fusion it recruits beta-catenin into a transcriptionally active nuclear complex independent of canonical Wnt signaling [PMID:16462762], destabilizes BMI1 to impair H2A ubiquitination and reactivate PcG targets [PMID:19337376], suppresses the anti-apoptotic genes MCL1 and BCL2A1 via ATF2/TLE1 binding at CRE promoter elements [PMID:22797074], derepresses E-cadherin by sequestering the repressor Slug from its promoter [PMID:16849535], activates EphB2/ephrin-mediated cytoskeletal remodeling [PMID:17686994], and reprograms mesenchymal stem cells toward a neural lineage in part through direct occupancy and upregulation of FGFR2 [PMID:21996728].","teleology":[{"year":1995,"claim":"Established that SSX2 is likely a transcriptional repressor by identifying a KRAB-like domain, providing the first functional hypothesis for an otherwise uncharacterized protein.","evidence":"Sequence analysis and structural homology identification","pmids":["7539744"],"confidence":"Medium","gaps":["Domain identification did not demonstrate repressor activity functionally","No DNA or chromatin targets defined"]},{"year":2002,"claim":"Identified the first direct SSX2 protein partners (RAB3IP and SSX2IP) via its N-terminal moiety and showed SSX2 can drive nuclear relocalization of RAB3IP, hinting at a role in protein subcellular distribution.","evidence":"Yeast two-hybrid, GST pull-down, immunofluorescence of transfected cells (single lab)","pmids":["12007189"],"confidence":"Medium","gaps":["Functional consequence of the interactions not defined","Not validated in endogenous tissue context"]},{"year":2006,"claim":"Defined how the SYT-SSX2 fusion deregulates transcription, showing it recruits beta-catenin to the nucleus independently of Wnt and sequesters the repressor Slug to derepress E-cadherin.","evidence":"Co-IP, ChIP, immunofluorescence, siRNA knockdown, luciferase reporter assays in synovial sarcoma cells","pmids":["16462762","16849535"],"confidence":"Medium","gaps":["Single-lab findings","Direct vs indirect nature of beta-catenin recruitment not fully resolved"]},{"year":2006,"claim":"Established the dual coactivator/corepressor logic of the fusion, showing SS18 contributes SWI/SNF association and SSX contributes Polycomb association, both retained in the fusion to deregulate histone modifications and DNA methylation.","evidence":"Conditional expression, microarray, ChIP for histone marks, bisulfite sequencing","pmids":["17018603"],"confidence":"Medium","gaps":["Mechanism of mark recruitment not resolved","Limited to CD44/IGF2 loci"]},{"year":2007,"claim":"Connected the fusion to a cytoskeletal phenotype, showing SYT-SSX2 activates EphB2/ephrin signaling driving neurite-like remodeling plus an independent microtubule-stabilizing effect.","evidence":"Retroviral transduction, EphB2 blockade rescue, immunofluorescence, patient tissue immunohistochemistry","pmids":["17686994"],"confidence":"Medium","gaps":["How transcriptional changes link to detyrosinated tubulin accumulation unclear","Single lab"]},{"year":2009,"claim":"Mechanistically linked the fusion to Polycomb antagonism by showing it destabilizes BMI1 and impairs H2A ubiquitination, reactivating PcG target genes.","evidence":"Co-IP, western blot for BMI1 stability, H2A ubiquitination assay, gene expression analysis","pmids":["19337376"],"confidence":"Medium","gaps":["Mechanism of BMI1 destabilization not defined","Direct vs indirect interaction unresolved"]},{"year":2011,"claim":"Showed SYT-SSX2 imposes a lineage program, directly occupying and upregulating neural genes including FGFR2 to commit mesenchymal progenitors to a pro-neural fate while blocking myogenic/adipogenic differentiation.","evidence":"Retroviral transduction, ChIP, expression profiling, shRNA knockdown with phenotypic rescue","pmids":["21996728"],"confidence":"Medium","gaps":["Full target gene network not mapped","Single lab"]},{"year":2012,"claim":"Established a druggable apoptotic axis and the genome-wide chromatin preference, showing SS18-SSX2 suppresses MCL1/BCL2A1 via ATF2/TLE1 at CRE elements (sensitizing to ABT-263) and binds predominantly H3K27me3-marked chromatin.","evidence":"ChIP and ChIP-seq, expression analysis, siRNA, cytotoxicity assay, in vivo model, hierarchical clustering","pmids":["22797074","22594313"],"confidence":"Medium","gaps":["Determinants of activation vs repression at H3K27me3 sites only partly explained by genomic position","Single lab"]},{"year":2014,"claim":"Characterized native (non-fusion) SSX2 as a non-specific dsDNA-binding chromatin protein that antagonizes PcG function and lowers H3K27me3, while ectopic expression triggers DNA damage, genomic instability, and p53-dependent senescence.","evidence":"PcG body imaging, ChIP for H3K27me3, in vitro DNA-binding, ectopic expression and knockdown, gamma-H2AX, senescence assays","pmids":["25249625","25363656"],"confidence":"Medium","gaps":["Indirect mechanism of PcG antagonism not molecularly defined","Source of genomic instability not pinpointed"]},{"year":2016,"claim":"Clarified that SSX2 modulates adhesion and dissemination rather than canonical EMT, with knockdown altering focal adhesion gene expression, invasion, and in vivo tumorigenicity in prostate cancer.","evidence":"Knockdown/overexpression, morphology, expression profiling, invasion and in vivo tumorigenicity assays","pmids":["27276714"],"confidence":"Medium","gaps":["Direct transcriptional targets for focal adhesion genes not identified","Tissue-context dependence unclear"]},{"year":2019,"claim":"Identified the Mediator complex as a specific effector of SSX2-induced senescence, distinguishing it from oncogene- or chemotherapy-induced senescence pathways.","evidence":"Functional genetic screen, siRNA of MED1/MED4/MED14, senescence assays with specificity controls","pmids":["31695025"],"confidence":"Medium","gaps":["How SSX2 engages Mediator mechanistically not defined","Single lab"]},{"year":2021,"claim":"Reported a distinct cell-biological consequence of SSX2 expression — S-phase-dependent intranuclear lamin bodies independent of its Polycomb or Mediator activities.","evidence":"Immunofluorescence in breast epithelial cells, pharmacological S-phase block, component exclusion (single lab)","pmids":["34808373"],"confidence":"Low","gaps":["Mechanism of lamin body formation remains indirect and immunofluorescence-based","Functional significance unknown"]},{"year":null,"claim":"The molecular basis by which native SSX2 reads chromatin and indirectly antagonizes Polycomb, and how this is mechanistically distinct from the fusion-driven program, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of SSX2 on chromatin","No defined sequence-specific or mark-specific recruitment mechanism","Native SSX2 partners beyond RAB3IP/SSX2IP largely uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,4,8]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,10,15]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[9,10]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[6,9,10]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,4,8]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[11,13]}],"complexes":[],"partners":["RAB3IP","SSX2IP","CTNNB1","SNAI2","BMI1","ATF2","TLE1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16385","full_name":"Protein SSX2","aliases":["Cancer/testis antigen 5.2","CT5.2","Synovial sarcoma, X breakpoint 2","Tumor antigen HOM-MEL-40"],"length_aa":188,"mass_kda":21.6,"function":"Could act as a modulator of transcription","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q16385/entry"},"depmap":{"release":"DepMap","has_data":false,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SSX2"},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SSX2","total_profiled":1310},"omim":[{"mim_id":"612409","title":"RNA-BINDING MOTIF PROTEIN 14; RBM14","url":"https://www.omim.org/entry/612409"},{"mim_id":"608690","title":"SSX2-INTERACTING PROTEIN; SSX2IP","url":"https://www.omim.org/entry/608690"},{"mim_id":"608686","title":"RAB3A-INTERACTING PROTEIN; RAB3IP","url":"https://www.omim.org/entry/608686"},{"mim_id":"606473","title":"SS18-LIKE GENE 2; SS18L2","url":"https://www.omim.org/entry/606473"},{"mim_id":"600192","title":"SS18 SUBUNIT OF BAF CHROMATIN REMODELING COMPLEX; SS18","url":"https://www.omim.org/entry/600192"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nucleoli","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"testis","ntpm":15.6}],"url":"https://www.proteinatlas.org/search/SSX2"},"hgnc":{"alias_symbol":["HOM-MEL-40","HD21","MGC3884","MGC15364","MGC119055","CT5.2a"],"prev_symbol":["SSX"]},"alphafold":{"accession":"Q16385","domains":[{"cath_id":"-","chopping":"20-72","consensus_level":"high","plddt":93.6568,"start":20,"end":72}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16385","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16385-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16385-F1-predicted_aligned_error_v6.png","plddt_mean":68.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SSX2","jax_strain_url":"https://www.jax.org/strain/search?query=SSX2"},"sequence":{"accession":"Q16385","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16385.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16385/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16385"}},"corpus_meta":[{"pmid":"7539744","id":"PMC_7539744","title":"Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7539744","citation_count":412,"is_preprint":false},{"pmid":"8840996","id":"PMC_8840996","title":"The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8840996","citation_count":193,"is_preprint":false},{"pmid":"7495284","id":"PMC_7495284","title":"Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript.","date":"1995","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7495284","citation_count":137,"is_preprint":false},{"pmid":"16849535","id":"PMC_16849535","title":"SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16849535","citation_count":95,"is_preprint":false},{"pmid":"17018603","id":"PMC_17018603","title":"The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17018603","citation_count":82,"is_preprint":false},{"pmid":"26041735","id":"PMC_26041735","title":"PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.","date":"2015","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/26041735","citation_count":72,"is_preprint":false},{"pmid":"24457462","id":"PMC_24457462","title":"Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.","date":"2014","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24457462","citation_count":60,"is_preprint":false},{"pmid":"21996728","id":"PMC_21996728","title":"Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21996728","citation_count":57,"is_preprint":false},{"pmid":"16462762","id":"PMC_16462762","title":"The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16462762","citation_count":57,"is_preprint":false},{"pmid":"12007189","id":"PMC_12007189","title":"The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP.","date":"2002","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12007189","citation_count":54,"is_preprint":false},{"pmid":"17929270","id":"PMC_17929270","title":"Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.","date":"2007","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/17929270","citation_count":42,"is_preprint":false},{"pmid":"11422798","id":"PMC_11422798","title":"Primary synovial sarcoma of the kidney: Report of a case confirmed by molecular detection of the SYT-SSX2 fusion transcripts.","date":"2001","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/11422798","citation_count":39,"is_preprint":false},{"pmid":"22797074","id":"PMC_22797074","title":"SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22797074","citation_count":34,"is_preprint":false},{"pmid":"25363656","id":"PMC_25363656","title":"Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25363656","citation_count":33,"is_preprint":false},{"pmid":"12037676","id":"PMC_12037676","title":"Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12037676","citation_count":32,"is_preprint":false},{"pmid":"21904219","id":"PMC_21904219","title":"Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.","date":"2011","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/21904219","citation_count":32,"is_preprint":false},{"pmid":"22594313","id":"PMC_22594313","title":"Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2.","date":"2012","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22594313","citation_count":31,"is_preprint":false},{"pmid":"26259251","id":"PMC_26259251","title":"β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26259251","citation_count":30,"is_preprint":false},{"pmid":"19337376","id":"PMC_19337376","title":"The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19337376","citation_count":26,"is_preprint":false},{"pmid":"17686994","id":"PMC_17686994","title":"The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway.","date":"2007","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17686994","citation_count":24,"is_preprint":false},{"pmid":"12505262","id":"PMC_12505262","title":"Cryptic t(X;18), ins(6;18), and SYT-SSX2 gene fusion in a case of intraneural monophasic synovial sarcoma.","date":"2002","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12505262","citation_count":24,"is_preprint":false},{"pmid":"11207827","id":"PMC_11207827","title":"Calcifying/ossifying synovial sarcoma shows t(X;18) with SSX2 involvement and mitochondrial calcifications.","date":"2001","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/11207827","citation_count":24,"is_preprint":false},{"pmid":"17509396","id":"PMC_17509396","title":"Primary monophasic synovial sarcoma of the duodenum with SYT/SSX2 type of translocation.","date":"2007","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17509396","citation_count":21,"is_preprint":false},{"pmid":"24681846","id":"PMC_24681846","title":"Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24681846","citation_count":19,"is_preprint":false},{"pmid":"15382048","id":"PMC_15382048","title":"Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.","date":"2004","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15382048","citation_count":19,"is_preprint":false},{"pmid":"25249625","id":"PMC_25249625","title":"SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25249625","citation_count":18,"is_preprint":false},{"pmid":"24645645","id":"PMC_24645645","title":"SSX2-4 expression in early-stage non-small cell lung cancer.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/24645645","citation_count":17,"is_preprint":false},{"pmid":"25078248","id":"PMC_25078248","title":"Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.","date":"2014","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/25078248","citation_count":17,"is_preprint":false},{"pmid":"14677925","id":"PMC_14677925","title":"Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.","date":"2003","source":"Cancer immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14677925","citation_count":16,"is_preprint":false},{"pmid":"34729377","id":"PMC_34729377","title":"Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia.","date":"2021","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/34729377","citation_count":16,"is_preprint":false},{"pmid":"15153546","id":"PMC_15153546","title":"Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15153546","citation_count":16,"is_preprint":false},{"pmid":"24492013","id":"PMC_24492013","title":"DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.","date":"2014","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/24492013","citation_count":15,"is_preprint":false},{"pmid":"15596411","id":"PMC_15596411","title":"Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.","date":"2005","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/15596411","citation_count":15,"is_preprint":false},{"pmid":"8773470","id":"PMC_8773470","title":"Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors.","date":"1996","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8773470","citation_count":14,"is_preprint":false},{"pmid":"12469233","id":"PMC_12469233","title":"Real-time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: report of 25 cases from St. Jude Children's Research Hospital.","date":"2002","source":"Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society","url":"https://pubmed.ncbi.nlm.nih.gov/12469233","citation_count":14,"is_preprint":false},{"pmid":"22344619","id":"PMC_22344619","title":"Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERα signaling.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22344619","citation_count":13,"is_preprint":false},{"pmid":"18992642","id":"PMC_18992642","title":"Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma.","date":"2008","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/18992642","citation_count":13,"is_preprint":false},{"pmid":"21630107","id":"PMC_21630107","title":"A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.","date":"2011","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/21630107","citation_count":12,"is_preprint":false},{"pmid":"22007079","id":"PMC_22007079","title":"Synovial sarcoma of the tongue confirmed by molecular detection of the SYT-SSX2 fusion gene transcript.","date":"2011","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22007079","citation_count":12,"is_preprint":false},{"pmid":"34538011","id":"PMC_34538011","title":"Undifferentiated sarcoma of bone with a round to epithelioid cell phenotype harboring a novel EWSR1-SSX2 fusion identified by RNA-based next-generation sequencing.","date":"2021","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34538011","citation_count":11,"is_preprint":false},{"pmid":"30186454","id":"PMC_30186454","title":"Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins.","date":"2018","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30186454","citation_count":10,"is_preprint":false},{"pmid":"30005870","id":"PMC_30005870","title":"Rab3IP interacts with SSX2 and enhances the invasiveness of gastric cancer cells.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30005870","citation_count":10,"is_preprint":false},{"pmid":"17931884","id":"PMC_17931884","title":"Expression and purification of the cancer antigen SSX2: a potential cancer vaccine.","date":"2007","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/17931884","citation_count":8,"is_preprint":false},{"pmid":"16682293","id":"PMC_16682293","title":"A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma.","date":"2006","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16682293","citation_count":8,"is_preprint":false},{"pmid":"27276714","id":"PMC_27276714","title":"SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27276714","citation_count":8,"is_preprint":false},{"pmid":"12201571","id":"PMC_12201571","title":"A rare synovial sarcoma of the kidney exhibiting translocation (X;18) and SYT-SSX2 fusion gene.","date":"2002","source":"Zhonghua yi xue za zhi = Chinese medical journal; Free China ed","url":"https://pubmed.ncbi.nlm.nih.gov/12201571","citation_count":8,"is_preprint":false},{"pmid":"12683902","id":"PMC_12683902","title":"SYT-SSX2 variant of primary pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a poor clinical outcome.","date":"2003","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12683902","citation_count":7,"is_preprint":false},{"pmid":"12521124","id":"PMC_12521124","title":"Expression of SSX-2 and SSX-4 genes in neuroblastoma.","date":"2002","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/12521124","citation_count":6,"is_preprint":false},{"pmid":"20830232","id":"PMC_20830232","title":"Primary pulmonary biphasic synovial sarcoma confirmed by molecular detection of a SYT-SSX2 fusion gene: report of 1 case.","date":"2010","source":"The Korean journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20830232","citation_count":5,"is_preprint":false},{"pmid":"19826807","id":"PMC_19826807","title":"Improved secretion of the cancer-testis antigen SSX2 in Pichia pastoris by deletion of its nuclear localization signal.","date":"2009","source":"Applied microbiology and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/19826807","citation_count":5,"is_preprint":false},{"pmid":"15350633","id":"PMC_15350633","title":"Are there geographical differences in the frequency of SYT-SSX1 and SYT-SSX2 chimeric transcripts in synovial sarcoma?","date":"2004","source":"Cancer detection and prevention","url":"https://pubmed.ncbi.nlm.nih.gov/15350633","citation_count":5,"is_preprint":false},{"pmid":"18626152","id":"PMC_18626152","title":"A t(X; 18) SYT-SSX2 positive synovial sarcoma in the pelvis of a young adult male: a rare case report with review of literature.","date":"2008","source":"Indian journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18626152","citation_count":5,"is_preprint":false},{"pmid":"31695025","id":"PMC_31695025","title":"A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31695025","citation_count":4,"is_preprint":false},{"pmid":"32691176","id":"PMC_32691176","title":"Primary monophasic synovial sarcoma of the cervical esophagus confirmed by detection of the SS18-SSX2 fusion transcripts: case report and literature review.","date":"2020","source":"Surgical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/32691176","citation_count":4,"is_preprint":false},{"pmid":"23109999","id":"PMC_23109999","title":"Primary Monophasic Synovial Sarcoma Arising in the Mesentery: Case Report of an Extremely Rare Mesenteric Sarcoma Confirmed by Molecular Detection of a SYT-SSX2 Fusion Transcript.","date":"2012","source":"Korean journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23109999","citation_count":4,"is_preprint":false},{"pmid":"29325767","id":"PMC_29325767","title":"Primary Synovial Sarcoma arising from gingivo-buccal sulcus harbouring SS18-SSX2 positive fusion transcript: The 1st reported case in English literature.","date":"2018","source":"Journal of stomatology, oral and maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/29325767","citation_count":3,"is_preprint":false},{"pmid":"22393780","id":"PMC_22393780","title":"[Analysis of SYT/SSX1 and SYT/SSX2 fusion genes from synovial sarcoma].","date":"2011","source":"Molekuliarnaia biologiia","url":"https://pubmed.ncbi.nlm.nih.gov/22393780","citation_count":2,"is_preprint":false},{"pmid":"34808373","id":"PMC_34808373","title":"SSX2 promotes the formation of a novel type of intranuclear lamin bodies.","date":"2021","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34808373","citation_count":1,"is_preprint":false},{"pmid":"41662627","id":"PMC_41662627","title":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.","date":"2026","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/41662627","citation_count":0,"is_preprint":false},{"pmid":"15854347","id":"PMC_15854347","title":"[Expression of SSX2 gene in human urologic neoplasms].","date":"2005","source":"Zhonghua wai ke za zhi [Chinese journal of surgery]","url":"https://pubmed.ncbi.nlm.nih.gov/15854347","citation_count":0,"is_preprint":false},{"pmid":"16837900","id":"PMC_16837900","title":"Expression of SSX2 tumor antigen in baculovirus expression system and its application for screening of blood serum of melanoma patients.","date":"2006","source":"Experimental oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16837900","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":30552,"output_tokens":3996,"usd":0.075798,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11847,"output_tokens":3927,"usd":0.078705,"stage2_stop_reason":"end_turn"},"total_usd":0.154503,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"SSX2 protein contains an N-terminal domain with homology to the Kruppel-associated box (KRAB), a transcriptional repressor domain previously found only in Kruppel-type zinc finger proteins, establishing SSX2 as a putative transcriptional repressor.\",\n      \"method\": \"Sequence analysis and structural homology identification\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — sequence-based domain identification replicated across multiple independent studies confirming KRAB-like domain\",\n      \"pmids\": [\"7539744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SSX2 physically interacts with two novel proteins, RAB3IP (human homologue of a Ras-like GTPase Rab3A interactor) and SSX2IP, via its N-terminal moiety; RAB3IP is normally cytoplasmic but co-expression with SSX2 results in its nuclear relocalization; both interactions were confirmed by yeast two-hybrid and GST pull-down assays in vitro.\",\n      \"method\": \"Yeast two-hybrid, GST pull-down, immunofluorescence of transfected cells\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal methods (yeast two-hybrid + in vitro GST pull-down + co-localization), single lab\",\n      \"pmids\": [\"12007189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The SYT-SSX2 fusion protein recruits beta-catenin to the nucleus and forms a transcriptionally active nuclear complex with beta-catenin; depletion of SYT-SSX2 in primary synovial sarcoma cells caused loss of nuclear beta-catenin signal and decreased beta-catenin signaling activity. This nuclear localization was independent of canonical Wnt signaling pathways.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, siRNA knockdown in primary synovial sarcoma cells, luciferase reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, KD with defined phenotype, reporter assay; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16462762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SYT-SSX2 interacts preferentially with the transcriptional repressor Slug (not Snail), preventing Slug from binding the proximal E-cadherin promoter, thereby derepressing E-cadherin transcription; this was shown by co-immunoprecipitation and chromatin immunoprecipitation, and confirmed by luciferase reporter assays showing SYT-SSX2 overcomes Slug-mediated E-cadherin repression.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP, and reporter assay in single lab with three orthogonal methods\",\n      \"pmids\": [\"16849535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The SS18-SSX2 fusion protein acts as a transcriptional activator-repressor that induces epigenetic gene deregulation, including altered histone modifications at the CD44 and IGF2 promoters and changes in DNA methylation at the IGF2 imprinting control region; SS18 normally associates with SWI/SNF (coactivator) and SSX associates with polycomb (corepressor), and both activities are retained in the fusion protein.\",\n      \"method\": \"Conditional expression + cDNA microarray profiling, chromatin immunoprecipitation for histone modifications, bisulfite sequencing for DNA methylation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal epigenetic assays, single lab\",\n      \"pmids\": [\"17018603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SYT-SSX2 activates the ephrin (Eph/ephrin) signaling pathway, causing cytoskeletal remodeling including cell elongation and neurite-like extensions; blockade of EphB2 signaling reversed this aberrant cytoskeletal phenotype. Additionally, SYT-SSX2 independently stabilizes the microtubule network via accumulation of detyrosinated Glu-tubulin in a manner independent of ephrin signaling.\",\n      \"method\": \"Retroviral transduction, EphB2 blockade rescue experiment, immunofluorescence, immunohistochemistry of patient tissue\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional rescue by pathway blockade, two distinct mechanisms identified, single lab\",\n      \"pmids\": [\"17686994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SYT-SSX2 interacts with the polycomb repressive complex and destabilizes the polycomb subunit Bmi1, resulting in impairment of polycomb-associated histone H2A ubiquitination and reactivation of polycomb target genes.\",\n      \"method\": \"Co-immunoprecipitation, western blot for Bmi1 stability, histone H2A ubiquitination assay, gene expression analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional histone modification assay plus target gene reactivation, single lab\",\n      \"pmids\": [\"19337376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SYT-SSX2 reprograms mesenchymal stem cells (BMMSCs) and myogenic progenitors by directly occupying and upregulating neural-specific genes, committing cells to a pro-neural lineage while simultaneously impairing myogenic and adipogenic differentiation; FGFR2 was identified as a direct target gene occupied and upregulated by SYT-SSX2, and knockdown of FGFR2 abrogated growth and attenuated the neural phenotype in BMMSCs and synovial sarcoma cells.\",\n      \"method\": \"Retroviral transduction, ChIP, gene expression profiling, shRNA knockdown with phenotypic readout\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct occupancy, KD rescue, multiple cell types; single lab\",\n      \"pmids\": [\"21996728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SS18-SSX2 directly suppresses expression of MCL1 and BCL2A1 anti-apoptotic genes by binding through ATF2 to cyclic AMP response elements (CRE) in their promoters and recruiting TLE1/Groucho, while concurrently increasing BCL2 expression; this pathway suppression renders synovial sarcoma cells sensitive to BH3-peptidomimetic ABT-263.\",\n      \"method\": \"ChIP, gene expression analysis, siRNA knockdown, in vitro cytotoxicity assay, in vivo mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct promoter binding with ATF2, functional pharmacological validation in vitro and in vivo; single lab\",\n      \"pmids\": [\"22797074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SYT-SSX2 is recruited genome-wide predominantly to Polycomb-modified chromatin enriched with H3K27me3; H3K27me3 is the dominant epigenetic marker associated with SYT-SSX2 binding and gene expression regulation, and activated target genes tend to have SYT-SSX2/H3K27me3 sites within the gene body or near the TSS, while repressed genes show SYT-SSX2/H3K27me3 at long-range.\",\n      \"method\": \"Genome-wide ChIP-seq, epigenetic profiling, hierarchical clustering\",\n      \"journal\": \"BMC genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq with multiple histone marks; single lab\",\n      \"pmids\": [\"22594313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SSX2 is a chromatin-associated protein that antagonizes BMI1 and EZH2 polycomb group (PcG) body formation, derepresses PcG target genes, and negatively regulates H3K27me3 levels in melanoma cells; SSX2 binds double-stranded DNA in a sequence non-specific manner; the antagonism of PcG function occurs through an indirect mechanism (likely modulation of chromatin structure) since SSX2 does not affect the overall composition and stability of PcG complexes.\",\n      \"method\": \"Immunofluorescence for PcG bodies, ChIP for H3K27me3, gene expression analysis, in vitro DNA-binding assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (ChIP, direct DNA-binding, PcG body imaging, gene expression), single lab\",\n      \"pmids\": [\"25249625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Ectopic SSX2 expression in melanoma and breast cancer cells causes DNA damage, genomic instability (increased DNA content, enlarged nuclei, DNA double-strand breaks), p53-mediated G1 cell cycle arrest, and late apoptosis/senescence; knockdown of endogenous SSX2 in melanoma cell lines reduced cell growth, demonstrating that SSX2 supports tumor cell proliferation.\",\n      \"method\": \"Ectopic overexpression and siRNA knockdown, flow cytometry, γH2AX immunostaining for DNA damage, β-galactosidase senescence assay\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional (OE + KD) with multiple phenotypic readouts; single lab\",\n      \"pmids\": [\"25363656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SSX2 knockdown in prostate cancer cells resulted in epithelial morphology, increased cell proliferation, increased expression of focal adhesion genes, decreased anchorage-independent growth, increased invasion, and increased in vivo tumorigenicity; overexpression had little effect on morphology. SSX2 does not drive epithelial-to-mesenchymal transition (EMT) in prostate cancer but is involved in focal adhesion loss associated with tumor cell dissemination.\",\n      \"method\": \"Knockdown and overexpression in prostate cancer cell lines, morphological analysis, gene expression profiling, invasion assay, in vivo tumorigenicity assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional genetic manipulation with multiple orthogonal phenotypic assays including in vivo; single lab\",\n      \"pmids\": [\"27276714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The Mediator complex is essential for SSX2-induced senescence: knockdown of MED1, MED4, and MED14 prevented SSX2-induced senescence in cancer cells, whereas MED1 knockdown did not prevent B-Raf- or Epirubicin-induced senescence, indicating a specific link between Mediator and SSX2-mediated senescence.\",\n      \"method\": \"Functional genetic screen, siRNA knockdown of Mediator subunits, senescence assays (β-galactosidase, morphology), specificity controls\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional genetic screen plus orthogonal validation with specificity controls; single lab\",\n      \"pmids\": [\"31695025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ectopic SSX2 expression induces the formation of a novel type of intranuclear lamin bodies containing both A- and B-type lamins but no other nuclear lamina components; this lamin body formation is dependent on S-phase progression and is independent of SSX2 interactions with polycomb proteins or the Mediator complex.\",\n      \"method\": \"Immunofluorescence in breast epithelial cell lines, pharmacological S-phase block, component exclusion analysis\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, primarily immunofluorescence-based localization; mechanism of lamin body formation remains indirect\",\n      \"pmids\": [\"34808373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The C-terminal nuclear localization signal (NLS) of SSX2 is required for its nuclear import; deletion of the NLS prevented nuclear localization and instead SSX2 accumulated in the endoplasmic reticulum in a misfolded state, while NLS-deleted SSX2 was correctly folded and secreted.\",\n      \"method\": \"Heterologous expression in Pichia pastoris, indirect immunofluorescence, deletion mutagenesis\",\n      \"journal\": \"Applied microbiology and biotechnology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional NLS identification by deletion, but performed in a yeast expression system for recombinant protein production purposes; single study\",\n      \"pmids\": [\"19826807\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SSX2 is a nuclear, chromatin-associated transcriptional repressor that contains a KRAB-like domain, binds double-stranded DNA non-specifically, antagonizes polycomb group complex function (destabilizing Bmi1, reducing H3K27me3, derepressing PcG target genes), and — as the SYT-SSX2 oncogenic fusion — recruits beta-catenin to the nucleus, activates ephrin/EphB2-mediated cytoskeletal remodeling, suppresses MCL1/BCL2A1 via ATF2/TLE1 at CRE promoter elements, derepresses E-cadherin by sequestering Slug from its promoter, and reprograms mesenchymal stem cells toward a neural lineage by directly occupying H3K27me3-marked chromatin genome-wide; in its native (non-fusion) form, SSX2 supports tumor cell proliferation and induces genomic instability and senescence through a Mediator complex-dependent pathway.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SSX2 is a nuclear, chromatin-associated transcriptional repressor that antagonizes Polycomb group (PcG) function and modulates chromatin structure [#0, #10]. It carries an N-terminal KRAB-like repressor domain [#0] and binds double-stranded DNA in a sequence non-specific manner, antagonizing BMI1/EZH2 PcG body formation, derepressing PcG target genes, and lowering H3K27me3 levels through an indirect mechanism that does not alter the composition or stability of PcG complexes [#10]. In its native form, SSX2 supports tumor cell proliferation but, when ectopically expressed, induces DNA damage, genomic instability, and p53-dependent senescence, the latter requiring the Mediator complex (MED1/MED4/MED14) [#11, #13]. SSX2 also drives context-dependent changes in tumor cell adhesion and dissemination distinct from canonical EMT [#12]. As the SYT(SS18)-SSX2 oncogenic fusion characteristic of synovial sarcoma, SSX2 contributes a Polycomb-corepressor activity combined with the SS18 SWI/SNF-coactivator activity to deregulate chromatin and gene expression genome-wide, binding preferentially to H3K27me3-marked chromatin [#4, #9]; through this fusion it recruits beta-catenin into a transcriptionally active nuclear complex independent of canonical Wnt signaling [#2], destabilizes BMI1 to impair H2A ubiquitination and reactivate PcG targets [#6], suppresses the anti-apoptotic genes MCL1 and BCL2A1 via ATF2/TLE1 binding at CRE promoter elements [#8], derepresses E-cadherin by sequestering the repressor Slug from its promoter [#3], activates EphB2/ephrin-mediated cytoskeletal remodeling [#5], and reprograms mesenchymal stem cells toward a neural lineage in part through direct occupancy and upregulation of FGFR2 [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that SSX2 is likely a transcriptional repressor by identifying a KRAB-like domain, providing the first functional hypothesis for an otherwise uncharacterized protein.\",\n      \"evidence\": \"Sequence analysis and structural homology identification\",\n      \"pmids\": [\"7539744\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Domain identification did not demonstrate repressor activity functionally\", \"No DNA or chromatin targets defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified the first direct SSX2 protein partners (RAB3IP and SSX2IP) via its N-terminal moiety and showed SSX2 can drive nuclear relocalization of RAB3IP, hinting at a role in protein subcellular distribution.\",\n      \"evidence\": \"Yeast two-hybrid, GST pull-down, immunofluorescence of transfected cells (single lab)\",\n      \"pmids\": [\"12007189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of the interactions not defined\", \"Not validated in endogenous tissue context\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined how the SYT-SSX2 fusion deregulates transcription, showing it recruits beta-catenin to the nucleus independently of Wnt and sequesters the repressor Slug to derepress E-cadherin.\",\n      \"evidence\": \"Co-IP, ChIP, immunofluorescence, siRNA knockdown, luciferase reporter assays in synovial sarcoma cells\",\n      \"pmids\": [\"16462762\", \"16849535\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab findings\", \"Direct vs indirect nature of beta-catenin recruitment not fully resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established the dual coactivator/corepressor logic of the fusion, showing SS18 contributes SWI/SNF association and SSX contributes Polycomb association, both retained in the fusion to deregulate histone modifications and DNA methylation.\",\n      \"evidence\": \"Conditional expression, microarray, ChIP for histone marks, bisulfite sequencing\",\n      \"pmids\": [\"17018603\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of mark recruitment not resolved\", \"Limited to CD44/IGF2 loci\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected the fusion to a cytoskeletal phenotype, showing SYT-SSX2 activates EphB2/ephrin signaling driving neurite-like remodeling plus an independent microtubule-stabilizing effect.\",\n      \"evidence\": \"Retroviral transduction, EphB2 blockade rescue, immunofluorescence, patient tissue immunohistochemistry\",\n      \"pmids\": [\"17686994\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How transcriptional changes link to detyrosinated tubulin accumulation unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mechanistically linked the fusion to Polycomb antagonism by showing it destabilizes BMI1 and impairs H2A ubiquitination, reactivating PcG target genes.\",\n      \"evidence\": \"Co-IP, western blot for BMI1 stability, H2A ubiquitination assay, gene expression analysis\",\n      \"pmids\": [\"19337376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of BMI1 destabilization not defined\", \"Direct vs indirect interaction unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed SYT-SSX2 imposes a lineage program, directly occupying and upregulating neural genes including FGFR2 to commit mesenchymal progenitors to a pro-neural fate while blocking myogenic/adipogenic differentiation.\",\n      \"evidence\": \"Retroviral transduction, ChIP, expression profiling, shRNA knockdown with phenotypic rescue\",\n      \"pmids\": [\"21996728\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Full target gene network not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established a druggable apoptotic axis and the genome-wide chromatin preference, showing SS18-SSX2 suppresses MCL1/BCL2A1 via ATF2/TLE1 at CRE elements (sensitizing to ABT-263) and binds predominantly H3K27me3-marked chromatin.\",\n      \"evidence\": \"ChIP and ChIP-seq, expression analysis, siRNA, cytotoxicity assay, in vivo model, hierarchical clustering\",\n      \"pmids\": [\"22797074\", \"22594313\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Determinants of activation vs repression at H3K27me3 sites only partly explained by genomic position\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Characterized native (non-fusion) SSX2 as a non-specific dsDNA-binding chromatin protein that antagonizes PcG function and lowers H3K27me3, while ectopic expression triggers DNA damage, genomic instability, and p53-dependent senescence.\",\n      \"evidence\": \"PcG body imaging, ChIP for H3K27me3, in vitro DNA-binding, ectopic expression and knockdown, gamma-H2AX, senescence assays\",\n      \"pmids\": [\"25249625\", \"25363656\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Indirect mechanism of PcG antagonism not molecularly defined\", \"Source of genomic instability not pinpointed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Clarified that SSX2 modulates adhesion and dissemination rather than canonical EMT, with knockdown altering focal adhesion gene expression, invasion, and in vivo tumorigenicity in prostate cancer.\",\n      \"evidence\": \"Knockdown/overexpression, morphology, expression profiling, invasion and in vivo tumorigenicity assays\",\n      \"pmids\": [\"27276714\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets for focal adhesion genes not identified\", \"Tissue-context dependence unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified the Mediator complex as a specific effector of SSX2-induced senescence, distinguishing it from oncogene- or chemotherapy-induced senescence pathways.\",\n      \"evidence\": \"Functional genetic screen, siRNA of MED1/MED4/MED14, senescence assays with specificity controls\",\n      \"pmids\": [\"31695025\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How SSX2 engages Mediator mechanistically not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Reported a distinct cell-biological consequence of SSX2 expression — S-phase-dependent intranuclear lamin bodies independent of its Polycomb or Mediator activities.\",\n      \"evidence\": \"Immunofluorescence in breast epithelial cells, pharmacological S-phase block, component exclusion (single lab)\",\n      \"pmids\": [\"34808373\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Mechanism of lamin body formation remains indirect and immunofluorescence-based\", \"Functional significance unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular basis by which native SSX2 reads chromatin and indirectly antagonizes Polycomb, and how this is mechanistically distinct from the fusion-driven program, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of SSX2 on chromatin\", \"No defined sequence-specific or mark-specific recruitment mechanism\", \"Native SSX2 partners beyond RAB3IP/SSX2IP largely uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 4, 8]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 10, 15]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [9, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [6, 9, 10]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 4, 8]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [11, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RAB3IP\", \"SSX2IP\", \"CTNNB1\", \"SNAI2\", \"BMI1\", \"ATF2\", \"TLE1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":5,"faith_total":5,"faith_pct":100.0}}